- Home
- XERS vs BIT Comparison
XERS vs BIT Comparison
Compare XERS & BIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- BIT
- Stock Information
- Founded
- XERS 2005
- BIT 2013
- Country
- XERS United States
- BIT United States
- Employees
- XERS N/A
- BIT N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- BIT Trusts Except Educational Religious and Charitable
- Sector
- XERS Health Care
- BIT Finance
- Exchange
- XERS Nasdaq
- BIT Nasdaq
- Market Cap
- XERS 526.3M
- BIT 590.7M
- IPO Year
- XERS 2018
- BIT N/A
- Fundamental
- Price
- XERS $4.24
- BIT $14.67
- Analyst Decision
- XERS Strong Buy
- BIT
- Analyst Count
- XERS 4
- BIT 0
- Target Price
- XERS $5.75
- BIT N/A
- AVG Volume (30 Days)
- XERS 2.4M
- BIT 92.4K
- Earning Date
- XERS 03-06-2025
- BIT 01-01-0001
- Dividend Yield
- XERS N/A
- BIT 9.36%
- EPS Growth
- XERS N/A
- BIT N/A
- EPS
- XERS N/A
- BIT N/A
- Revenue
- XERS $203,070,000.00
- BIT N/A
- Revenue This Year
- XERS $20.47
- BIT N/A
- Revenue Next Year
- XERS $19.35
- BIT N/A
- P/E Ratio
- XERS N/A
- BIT N/A
- Revenue Growth
- XERS 23.89
- BIT N/A
- 52 Week Low
- XERS $1.69
- BIT $13.65
- 52 Week High
- XERS $4.50
- BIT $15.97
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- BIT 47.53
- Support Level
- XERS $3.59
- BIT $14.64
- Resistance Level
- XERS $4.50
- BIT $14.76
- Average True Range (ATR)
- XERS 0.25
- BIT 0.08
- MACD
- XERS 0.03
- BIT -0.00
- Stochastic Oscillator
- XERS 72.34
- BIT 40.62
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About BIT BlackRock Multi-Sector Income Trust of Beneficial Interest
BlackRock Multi-Sector Income Trust is a closed-end investment management company. It invests on behalf of its clients. The fund's primary investment objective is to provide a high level of current income, with a secondary objective of capital appreciation. The company seeks to achieve its investment objectives by investing, under normal market conditions, a majority of its assets in loan and debt instruments and other investments with similar economic characteristics. Its portfolio consists of Corporate Bonds, Asset-Backed Securities, Preferred Securities and others.